Routine use of metabolic drug recommended for all kidney function levels
The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce the risk of kidney disease progression, hospitalization, and death in people with and without diabetes, regardless of their kidney function.This […]
